MediPharm Labs (OTCMKTS:MEDIF) Now Covered by BMO Capital Markets

Research analysts at BMO Capital Markets began coverage on shares of MediPharm Labs (OTCMKTS:MEDIF) in a research note issued to investors on Friday, The Fly reports. The brokerage set a “market perform” rating on the stock.

Separately, Canaccord Genuity dropped their price target on MediPharm Labs from $1.75 to $1.00 and set a “buy” rating on the stock in a research report on Thursday, April 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $1.38.

Shares of MediPharm Labs stock opened at $0.37 on Friday. The business’s 50 day simple moving average is $0.41 and its 200-day simple moving average is $0.51. MediPharm Labs has a twelve month low of $0.35 and a twelve month high of $1.53.

MediPharm Labs Company Profile

MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates, and advance derivative products in Canada and Australia. It formulates, processes, packages, and distributes cannabis extracts and cannabinoid-based products. The company was founded in 2015 and is headquartered in Barrie, Canada.

Read More: What is a conference call?

The Fly

Analyst Recommendations for MediPharm Labs (OTCMKTS:MEDIF)

Receive News & Ratings for MediPharm Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediPharm Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit